查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363247

肉瘤治療藥物市場規模、佔有率、趨勢分析報告：依治療類型、配銷通路、地區、細分趨勢，2023-2030

Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 93 Pages | 商品交期: 2-10個工作天內

價格

肉瘤治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球肉瘤治療市場規模將達到25.345億美元，2023年至2030年年複合成長率為8.9%。

市場成長主要是由新產品發布、新型療法的採用增加以及目標人口等要素所推動的。

肉瘤佔成人所有癌症的比例不到 1.0%。肉瘤是一個異質性群體，由 50 多種不同的組織學類型組成，但兩個主要亞型是軟組織肉瘤 (STS) 和骨癌。美國每年約有 12,000 人被診斷出患有 STS，歐洲每年約有 28,000 人被診斷出患有 STS。

40多年來，局部肉瘤的主要治療方法一直是手術切除，然後進行新輔助或輔助放射線治療和化療。然而，即使完全手術切除，大約 50.0% 的惡性肉瘤患者也會發生轉移。標靶治療的引入徹底改變了肉瘤的治療模式。在整個預測期內，標靶治療和管道突破將繼續在市場成長中發揮關鍵作用。

肉瘤藥物市場報告亮點

  • 到2022年，EU5仍將是第二大市場，佔有率將超過20%。此細分市場的成長歸因於 STS罹患率的上升、標靶治療的廣泛普及以及研發活動的活性化。
  • 禮來公司的 Lartuvo 已取代標準阿黴素療法作為 STS 的一線治療方法，預計在預測期內將保持其市場主導地位。
  • 該市場存在強烈的未滿足需求，為開發創新的一流治療方法創造了重要機會。在肉瘤管道中的 45 種藥物中，7 種處於 III 期，22 種處於 II 期，2 種處於 I/II 期試驗，其餘處於 I 期和臨床前試驗。
  • 目前正在 I/II 期臨床試驗中評估免疫腫瘤藥物在肉瘤中的潛在作用。
  • 階段階段的新標靶藥物包括諾華的Afinitor（mTOR抑制劑）、Tesaro的Zejula（PARP抑制劑）、安進的Imlygic（基因療法）、輝瑞的Crizotinib（ALK和MET酪胺酸激酶抑制劑）等。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 肉瘤藥物市場：變數、趨勢、範圍

  • 市場體系預測
  • 普及和成長預測圖
  • 產業價值鏈分析
  • 市場動態
  • 肉瘤藥物市場分析工具

第4章 肉瘤治療藥物市場：治療類型估計和趨勢分析

  • 肉瘤藥物市場：要點
  • 肉瘤藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 化療
  • 標靶治療

第5章 肉瘤治療藥物市場：配銷通路估算與趨勢分析

  • 肉瘤藥物市場：要點
  • 肉瘤藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第6章 肉瘤治療藥物市場：區域估計和趨勢分析

  • 區域預測
  • 肉瘤藥物市場：按地區：主要市場亮點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Pfizer Inc.
    • Novartis International AG
    • Eli Lilly and Company
    • Bayer AG
    • Eisai Co.
    • Johnson & Johnson
    • Merck & Co. Inc
    • Daiichi Sankyo Company, Limited
Product Code: GVR-2-68038-528-1

Sarcoma Drugs Market Growth & Trends:

The global sarcoma drugs market size is expected to be valued at USD 2534.5 million by 2030, as per a new report by Grand View Research, Inc.., progressing at a CAGR of 8.9% from 2023 to 2030. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.

Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year.

For over 40 years, the mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. The introduction of targeted therapy has revolutionized the treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period.

Sarcoma Drugs Market Report Highlights:

  • EU5 will remain the second largest market with more than 20% share by 2022. The growth of the segment can be attributed to the rising incidence of STS, uptake of targeted therapies, and increasing R&D activities
  • Eli Lilly's Lartuvo has displaced standard doxorubicin therapy as front-line STS treatment and is anticipated to maintain its prominence in the market over the forecast period
  • Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the remaining in Phase I and Pre-clinical trials
  • The potential role for use of immuno-oncology agents in sarcomas is currently under evaluation in Phase I/II clinical trials
  • Drugs with novel targets in early-phase development include Novartis's Afinitor (mTOR inhibitor), Tesaro's Zejula (PARP inhibitor), Amgen's Imlygic (gene therapy), and Pfizer's Crizotinib (ALK and MET tyrosine kinases inhibitor)

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment type
    • 1.1.2. Distribution channel
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment type outlook
    • 2.2.2. Distribution channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Sarcoma Drugs Market: Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
  • 3.5. Sarcoma Drugs Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic Landscape

Chapter 4. Sarcoma Drugs Market: Treatment Type Estimates & Trend Analysis

  • 4.1. Sarcoma Drugs Market: Key Takeaways
  • 4.2. Sarcoma Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Targeted therapy
    • 4.4.1. Targeted therapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Sarcoma Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Sarcoma Drugs Market: Key Takeaways
  • 5.2. Sarcoma Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospital pharmacy
    • 5.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Retail pharmacy
    • 5.4.1. Retail pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Online pharmacy
    • 5.5.1. Online pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Sarcoma Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Sarcoma Drugs Market: by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Pfizer Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Novartis International AG
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Eli Lilly and Company
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Bayer AG
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Eisai Co.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Johnson & Johnson
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Merck & Co. Inc
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Daiichi Sankyo Company, Limited
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 3 North America sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 4 North America sarcoma drugs market: by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 6 U.S. sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 Canada sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 8 Canada sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Europe sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 10 Europe sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Europe sarcoma drugs market: by region, 2018 - 2030 (USD Million)
  • Table 12 Germany sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 13 Germany sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 UK sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 15 UK sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 France sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 17 France sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 18 Italy sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 19 Italy sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Spain sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 21 Spain sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 Sweden sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 23 Sweden sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Norway sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 25 Norway sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Denmark sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 27 Denmark sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific sarcoma drugs market: by region, 2018 - 2030 (USD Million)
  • Table 31 China sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 32 China sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 China sarcoma drugs market: by application, 2018 - 2030 (USD Million)
  • Table 34 Japan sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 35 Japan sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Japan sarcoma drugs market: by application, 2018 - 2030 (USD Million)
  • Table 37 India sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 38 India sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Australia sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 40 Australia sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Thailand sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 42 Thailand sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 South Korea sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 44 South Korea sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Latin America sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 46 Latin America sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Latin America sarcoma drugs market: by region, 2018 - 2030 (USD Million)
  • Table 48 Brazil sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 49 Brazil sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Mexico sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 51 Mexico sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Argentina sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 53 Argentina sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 55 Middle East and Africa sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East and Africa sarcoma drugs market: by region, 2018 - 2030 (USD Million)
  • Table 57 South Africa sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 58 South Africa sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 UAE sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 62 UAE sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
  • Table 63 Kuwait sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
  • Table 64 Kuwait sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Sarcoma drugs market: Market outlook
  • Fig. 9 Sarcoma drugs market: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Sarcoma drugs market: driver impact
  • Fig. 15 Sarcoma drugs market: restraint impact
  • Fig. 16 Sarcoma drugs market: Strategic Initiatives analysis
  • Fig. 17 Sarcoma drugs market: Treatment type movement analysis
  • Fig. 18 Sarcoma drugs market: Treatment type outlook and key takeaways
  • Fig. 19 Chemotherapy market estimates and forecasts, 2018 - 2030
  • Fig. 20 Targeted therapy & others market estimates and forecasts, 2018 - 2030
  • Fig. 21 Sarcoma drugs market: Distribution channel movement analysis
  • Fig. 22 Sarcoma drugs market: Distribution channel outlook and key takeaways
  • Fig. 23 Hospital pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 24 Retail pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 25 Online pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 26 Global Sarcoma drugs market: Regional movement analysis
  • Fig. 27 Global Sarcoma drugs market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 31 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 32 UK market estimates and forecasts, 2018 - 2030
  • Fig. 33 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 34 France market estimates and forecasts, 2018 - 2030
  • Fig. 35 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 36 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 37 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 38 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 39 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 41 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 42 China market estimates and forecasts, 2018 - 2030
  • Fig. 43 India market estimates and forecasts, 2018 - 2030
  • Fig. 44 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 45 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 46 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 47 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 48 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 50 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 51 Middle East and Africa. market estimates and forecasts, 2018 - 2030
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 53 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 54 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030